Lower Limbs Peripheral Arterial DiseaseQFRNCT06516315
Feasibility Study of an Angiographic Quantitative Flow Ratio-guided Endovascular Procedure in Patients With Lower Limbs Peripheral Arterial Disease.
A study testing Preoperative ultrasound examination. and Peroperatoire angiography procedure and QFR analysis in people with Lower Limbs Peripheral Arterial Disease, run by Fondation Hôpital Saint-Joseph at 1 site in France.
Trial summary
The main objective of this study is to explore the feasibility of using the angiographic Quantitative Flow Ratio (QFR) as a tool to predict the success rate of endovascular revascularization in patients with superficial artery disease. This is a prospective feasibility study. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Lower Limbs Peripheral Arterial Disease
- What is being tested?
- Preoperative ultrasound examination. and Peroperatoire angiography procedure and QFR analysis
- Type of treatment
- Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 35 participants
- Where
- 1 siteFrance
- Study dates
- 29 Apr 2024to 24 May 2025
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Patient with symptomatic Rutherford stage 2 to 6 AOMI with an indication for endovascular revascularization
- Patient with a simple lesion (TASC A) and short stenosis of the superficial femoral artery
- Patient affiliated to a health insurance system
- French-speaking patient
- Patient with free, informed and express oral consent
Who cannot join
- Renal failure patients with GFR \< 30 ml/min
- Patient deprived of liberty
- Patients under court protection
- Pregnant or breast-feeding patients
Trial locations and contacts
1 site in 1 country.
France1 site, 1 recruiting
- Recruiting
Hôpital Paris Saint-Joseph - 185 Rue Raymond Losserand
Paris, Île-de-France Region, 750014
MICHELE LOHORE, crc@ghpsj.fr
About this study
The main objective of this study is to explore the feasibility of using the angiographic Quantitative Flow Ratio (QFR) as a tool to predict the success rate of endovascular revascularization in patients with superficial artery disease.
This is a prospective feasibility study. We aim to include 35 patients with indication for endovascular revascularization of a short stenosis of the superficial femoral artery. Intraoperative angiography will be performed immediately prior to revascularization. Quantitative analysis of angiography images will be performed post-procedure using Medis QFR®2.2 software.
Read the detailed description
Approximately 202 million people are affected with lower extremity artery disease (LEAD) worldwide, of whom almost 40 million are living in Europe. LEAD usually appears after the age of 50 years, with an exponential increase after the age of 65. This rate reaches around 20% by the age of 80. In most studies, the proportion of symptomatic LEAD is 1:3 to 1:5 of all LEA.
The global burden of LEAD is considerable. In 2010, the years of life lost due to LEAD were estimated at 31.7, 15.1, and 3.7 years per 100,000 inhabitants in Western, Central, and Eastern Europe, respectively.
During the two last decade, indications of endovascular approach of femoropopliteal lesions have dramatically increased, to become the gold standard with a first endo strategy approach. In 2000, endovascular treatment was recommended for stenosis ≤ 5cm or occlusions ≤ 3cm. Today, the guidelines suggest endo approach for lesion until 25 cm In 2019, in France, 50 000 patients underwent an endovascular femoral popliteal revascularization, and drug eluting devices (Stents or Balloons). According to the Excellence in Peripheral Artery Disease Registry, early stent occlusion is about 5% during the 6 first months after procedure. Success rate of endovascular procedure is high, but many thrombosis are due to incomplete endovascular treatment, leading to early re-occlusion. Usually, quality and success assessment are made by the operator, based on images provided by a single plan angiography. Vascular surgeons face a lack of devices helping us to appreciate the quality of our revascularization per procedure. Endovascular ultrasounds (IVUS) or Optical Coherence Tomography(OCT) are not reimbursed in many countries. These devices are quite expensive and, like the FFR, require the introduction of dedicated devices into the arteries, thus increasing procedure's duration.
Similar situation can be seen in patients undergoing coronary percutaneous coronary intervention (PCI), current evidence indicates post-PCI suboptimal results. However, the combination of quantitative vessel analysis (QVA) with angiography-derived fractional flow reserve (FFR) assessment has shown promising improvements in PCI outcomes. A notable non-invasive solution for angiography derived FFR is Quantitative Flow Ratio (QFR), which includes quantitative vessel analysis (QVA) reporting significant enhancement in revascularization therapy.
Extending its potential benefits, QFR emerges as a non-invasive and cost-effective solution to improve revascularization outcomes for lower extremities.
MAIN OBJECTIVE The main objective of this study is to explore the feasibility of using QFR as a tool to predict the success rate of endovascular revascularization in patients with superficial artery disease.
METHODS:
- Study design and Population This is a prospective feasibility study. We aim to include 35 patients with indication for endovascular revascularization of a short stenosis of the superficial femoral artery (TASC A, Rutherford stage 2 to 6). Intraoperative angiography will be performed immediately prior to revascularization. Quantitative analysis of angiography images will be performed post-procedure using Medis QFR®2.2 software.
- Clinical variables:
- Age
- Sex
- Height/Weight
- Previous medical history
- Rutherford classification
- TASC lesion (only for sfa)
- Procedure: - Type of treatment
- Stents (type, length, diameter, number)
- Amount of contrast
- Xray duration
- Xray Dose (Gy)
- Technical success
- Outcomes: 30 days patency
- Angiography procedure and acquisition protocol Selective PCI will be performed using standard catheterization according to European society of Cardiology guidelines for lower extremity artery disease. At least two projections angles separated at least 25 degrees were acquired for the optimal view of the lesions. Details of the acquisition protocol are described in appendix B.
- QCA and QFR analysis The 3D QCA and QFR analysis will be performed using a research version of software package QFR 2.2. QFR allows to match two diagnostic angiographic projections and create a 3D reconstruction of the interrogated vessel. From this reconstruction the following parameters will be derived: lesions length, QFR, delta(△) QFR, % diameter of stenosis, minimum lumen diameter, residual QFR, QFR pullback curve and derivative of QFR pullback curve (dQFR/ds).
- Conditions
- Lower Limbs Peripheral Arterial Disease
- Being tested
- Preoperative ultrasound examination., Peroperatoire angiography procedure and QFR analysis
- Keywords
- Lower Limbs Peripheral Arterial Disease, endovascular procedure, angiographic Quantitative Flow Ratio
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Preoperative ultrasound examination.Procedure or surgery
Preoperative ultrasound examination performed the day before or the day of surgery.
Peroperatoire angiography procedure and QFR analysisProcedure or surgery
Intraoperative angiography will be performed immediately prior to revascularization. Quantitative analysis of angiography images will be performed post-procedure using Medis QFR®2.2 software.
| Study group | Role | What they receive |
|---|---|---|
| qfr | Experimental | Patients with indication for endovascular revascularization of a short stenosis of the superficial femoral artery (TASC A, Rutherford stage 2 to 6) :
* Preoperative ultrasound, performed the day before or the day of surgery
* Intraoperative angiography performed immediately prior to revascularization (routine care procedure whose duration is extended by research)
* Quantitative analysis of angiography images will be performed post-procedure using Medis QFR®2.2 software. Receives: Procedure: Preoperative ultrasound examination.; Procedure: Peroperatoire angiography procedure and QFR analysis |
What is being measured
The primary outcome is the main question the study is designed to answer.
Preoperative systolic velocity peak and intraoperative QFR
Systolic velocity peak measured by preoperative ultrasound, performed the day before or the day of surgery, and QFR measured intraoperatively, immediately before the revascularization procedure.
Measured: Day -1, Day 0
Secondary outcomes (8)
Percentage of stenosis
Percentage of stenosis measured by preoperative ultrasound, performed the day before or the day of surgery.
Measured: Day -1, Day 0
Occurrence of a Major Adverse Limb Event (MALE)
Occurrence of a Major Adverse Limb Event (MALE) at 1 month post-op (D30): Acute ischemia OR Major amputation OR Re-intervention on revascularized limb (excluding minor amputation).
Measured: Day 30
Re-hospitalization
Re-hospitalization for any reason at 1 month post-procedure (D30).
Measured: Day 30
Revascularization
Revascularization (endovascular or surgical) of the treated area (Target Lesion Revascularization (TLR)) defined by re-intervention on the target lesion, including 1 cm above and below the target lesion.
Measured: Day 30
Rutherford classification
Rutherford classification at 1 month post-op.
Measured: Day 30
Dosimetry and dose of contrast medium
Dosimetry and dose of contrast medium injected during the procedure (D0).
Measured: Day 0
Procedure envisaged by surgeon
Procedure envisaged by surgeon 1 and procedure envisaged by surgeon 2 after reading the QFR.
Measured: Day 0
Creatinine levels and glomerular filtration rate
Preoperative (D0) and postoperative (D5 and D30) creatinine levels and glomerular filtration rate.
Measured: Day 5, Day 30
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted23 Jul 2024
- Study start29 Apr 2024
- Primary completion24 Apr 2025 (estimated)
- Study completion24 May 2025 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Lower Limbs Peripheral Arterial DiseaseStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Other
- Allocation
- Not applicable
- Intervention model
- Single group
- Model description
- Prospective feasibility study
- Masking
- None (open label)
- Enrolment
- 35 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Fondation Hôpital Saint-Joseph
- Sponsor type
- University, hospital or other
- Collaborators
- Medis Medical Imaging Systems B.V.
- Responsible party
- Sponsor
- Investigators
- Maxime RAUX, Principal investigator, Principal investigator, Fondation Hôpital Saint-Joseph
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06516315
- Sponsor's protocol ID
- 684_QFR
- Other IDs
- 2024-A00022-45
- Acronym
- QFR
- Status last verified
- Jul 2024
- First submitted
- 10 Jul 2024
- Last updated
- 23 Jul 2024
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 23 Jul 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Feasibility Study of an Angiographic Quantitative Flow Ratio-guided Endovascular Procedure in Patients With Lower Limbs Peripheral Arterial Disease.
- ClinicalTrials.gov ID
- NCT06516315
- Acronym / sponsor ID
- QFR / 684_QFR
- Conditions
- Lower Limbs Peripheral Arterial Disease
- Keywords
- Lower Limbs Peripheral Arterial Disease, endovascular procedure, angiographic Quantitative Flow Ratio
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 35 participants (estimated)
- Lead sponsor
- Fondation Hôpital Saint-JosephUniversity, hospital or other
- Collaborators
- Medis Medical Imaging Systems B.V.
- Study start
- 29 Apr 2024 (actual)
- Primary completion
- 24 Apr 2025 (estimated)
- Study completion
- 24 May 2025 (estimated)
- First posted
- 23 Jul 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The main objective of this study is to explore the feasibility of using the angiographic Quantitative Flow Ratio (QFR) as a tool to predict the success rate of endovascular revascularization in patients with superficial artery disease.
This is a prospective feasibility study. We aim to include 35 patients with indication for endovascular revascularization of a short stenosis of the superficial femoral artery. Intraoperative angiography will be performed immediately prior to revascularization. Quantitative analysis of angiography images will be performed post-procedure using Medis QFR®2.2 software.
Detailed description
Approximately 202 million people are affected with lower extremity artery disease (LEAD) worldwide, of whom almost 40 million are living in Europe. LEAD usually appears after the age of 50 years, with an exponential increase after the age of 65. This rate reaches around 20% by the age of 80. In most studies, the proportion of symptomatic LEAD is 1:3 to 1:5 of all LEA.
The global burden of LEAD is considerable. In 2010, the years of life lost due to LEAD were estimated at 31.7, 15.1, and 3.7 years per 100,000 inhabitants in Western, Central, and Eastern Europe, respectively.
During the two last decade, indications of endovascular approach of femoropopliteal lesions have dramatically increased, to become the gold standard with a first endo strategy approach. In 2000, endovascular treatment was recommended for stenosis ≤ 5cm or occlusions ≤ 3cm. Today, the guidelines suggest endo approach for lesion until 25 cm In 2019, in France, 50 000 patients underwent an endovascular femoral popliteal revascularization, and drug eluting devices (Stents or Balloons). According to the Excellence in Peripheral Artery Disease Registry, early stent occlusion is about 5% during the 6 first months after procedure. Success rate of endovascular procedure is high, but many thrombosis are due to incomplete endovascular treatment, leading to early re-occlusion. Usually, quality and success assessment are made by the operator, based on images provided by a single plan angiography. Vascular surgeons face a lack of devices helping us to appreciate the quality of our revascularization per procedure. Endovascular ultrasounds (IVUS) or Optical Coherence Tomography(OCT) are not reimbursed in many countries. These devices are quite expensive and, like the FFR, require the introduction of dedicated devices into the arteries, thus increasing procedure's duration.
Similar situation can be seen in patients undergoing coronary percutaneous coronary intervention (PCI), current evidence indicates post-PCI suboptimal results. However, the combination of quantitative vessel analysis (QVA) with angiography-derived fractional flow reserve (FFR) assessment has shown promising improvements in PCI outcomes. A notable non-invasive solution for angiography derived FFR is Quantitative Flow Ratio (QFR), which includes quantitative vessel analysis (QVA) reporting significant enhancement in revascularization therapy.
Extending its potential benefits, QFR emerges as a non-invasive and cost-effective solution to improve revascularization outcomes for lower extremities.
MAIN OBJECTIVE The main objective of this study is to explore the feasibility of using QFR as a tool to predict the success rate of endovascular revascularization in patients with superficial artery disease.
METHODS:
- Study design and Population This is a prospective feasibility study. We aim to include 35 patients with indication for endovascular revascularization of a short stenosis of the superficial femoral artery (TASC A, Rutherford stage 2 to 6). Intraoperative angiography will be performed immediately prior to revascularization. Quantitative analysis of angiography images will be performed post-procedure using Medis QFR®2.2 software.
- Clinical variables:
- Age
- Sex
- Height/Weight
- Previous medical history
- Rutherford classification
- TASC lesion (only for sfa)
- Procedure: - Type of treatment
- Stents (type, length, diameter, number)
- Amount of contrast
- Xray duration
- Xray Dose (Gy)
- Technical success
- Outcomes: 30 days patency
- Angiography procedure and acquisition protocol Selective PCI will be performed using standard catheterization according to European society of Cardiology guidelines for lower extremity artery disease. At least two projections angles separated at least 25 degrees were acquired for the optimal view of the lesions. Details of the acquisition protocol are described in appendix B.
- QCA and QFR analysis The 3D QCA and QFR analysis will be performed using a research version of software package QFR 2.2. QFR allows to match two diagnostic angiographic projections and create a 3D reconstruction of the interrogated vessel. From this reconstruction the following parameters will be derived: lesions length, QFR, delta(△) QFR, % diameter of stenosis, minimum lumen diameter, residual QFR, QFR pullback curve and derivative of QFR pullback curve (dQFR/ds).
Study design
- Primary purpose
- Other
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
- Model description
- Prospective feasibility study
| Arm | Type | Receives |
|---|---|---|
| qfr | Experimental | Procedure: Preoperative ultrasound examination., Procedure: Peroperatoire angiography procedure and QFR analysisPatients with indication for endovascular revascularization of a short stenosis of the superficial femoral artery (TASC A, Rutherford stage 2 to 6) : * Preoperative ultrasound, performed the day before or the day of surgery * Intraoperative angiography performed immediately prior to revascularization (routine care procedure whose duration is extended by research) * Quantitative analysis of angiography images will be performed post-procedure using Medis QFR®2.2 software. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (5 listed)
- Patient with symptomatic Rutherford stage 2 to 6 AOMI with an indication for endovascular revascularization
- Patient with a simple lesion (TASC A) and short stenosis of the superficial femoral artery
- Patient affiliated to a health insurance system
- French-speaking patient
- Patient with free, informed and express oral consent
Key exclusion criteria (4 listed)
- Renal failure patients with GFR \< 30 ml/min
- Patient deprived of liberty
- Patients under court protection
- Pregnant or breast-feeding patients
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Preoperative ultrasound examination.Preoperative ultrasound examination performed the day before or the day of surgery. | Procedure or surgery | qfr |
| Peroperatoire angiography procedure and QFR analysisIntraoperative angiography will be performed immediately prior to revascularization. Quantitative analysis of angiography images will be performed post-procedure using Medis QFR®2.2 software. | Procedure or surgery | qfr |
Primary outcome
Preoperative systolic velocity peak and intraoperative QFR
Time frame: Day -1, Day 0
Systolic velocity peak measured by preoperative ultrasound, performed the day before or the day of surgery, and QFR measured intraoperatively, immediately before the revascularization procedure.
8 secondary outcomes
Percentage of stenosis
Time frame: Day -1, Day 0
Occurrence of a Major Adverse Limb Event (MALE)
Time frame: Day 30
Re-hospitalization
Time frame: Day 30
Revascularization
Time frame: Day 30
Rutherford classification
Time frame: Day 30
Dosimetry and dose of contrast medium
Time frame: Day 0
Procedure envisaged by surgeon
Time frame: Day 0
Creatinine levels and glomerular filtration rate
Time frame: Day 5, Day 30
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 23 Jul 2024.
- Individual participant dataSharing planned: No
Related trials for Lower Limbs Peripheral Arterial Disease
RecruitingPhase 3
Reducing Adverse Vascular Outcomes With Factor XI Inhibition in Adult Participants With Peripheral Artery Disease
Peripheral Artery Disease (PAD)
Active, not recruiting
Thromboelastography With Platelet Mapping to Guide Antiplatelet Therapy After Lower Extremity Revascularization
Thrombosis, Arterial Occlusive Diseases
Recruiting
Construction and Empirical Research of a Risk Prediction Model for Preventing Lower Extremity Arteriosclerosis Obliterans in Diabetic Patients Based on the HAPA Model
Diabetes Mellitus, Peripheral Arterial Disease
RecruitingObservational study
SPECTATOR: Perfusion Monitoring Before, During and After Lower Extremity Revascularization With Laser Speckle Contrast Imaging
Vascular Disease,Peripheral
Not yet recruitingPhase 4
Seltoplasmid Plus Revascularization for Diabetic Infrapopliteal Chronic Limb-Threatening Ischemia
Chronic Limb-Threatening Ischemia, Diabetic Foot Ulcer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Maxime RAUX, Principal investigator principal investigator
Fondation Hôpital Saint-Joseph
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Preoperative ultrasound examination. and Peroperatoire angiography procedure and QFR analysis in people with Lower Limbs Peripheral Arterial Disease, run by Fondation Hôpital Saint-Joseph at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 23 Jul 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Michèle LOHORE (+ 331 44127883, crc@ghpsj.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Preoperative systolic velocity peak and intraoperative QFR (time frame: Day -1, Day 0). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 23 Jul 2024.